公司概述
Illumina, Inc. operates within the healthcare sector, specifically focusing on the diagnostics and research industry by providing sequencing- and array-based solutions for genetic and genomic analysis across the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company's core offerings include sequencing- and array-based instruments alongside essential consumables such as reagents, flow cells, and other necessary components for laboratory operations. This entity represents a significant market presence with a total market capitalization of $18.91B and reported annual revenue (TTM) of $4.34B, supported by an employee base of 8,600 professionals. These valuation and revenue figures indicate that Illumina maintains a substantial scale within its specialized niche, commanding a market capitalization that reflects investor confidence in its genomic technology infrastructure despite the high fixed costs inherent in manufacturing precision instruments.
财务健康
Illumina reported revenue of $4.34B (TTM), with net income reaching $850.00M and EBITDA standing at $1.14B, revealing a cost structure where operating expenses consume approximately 58.6% of total revenue before interest and taxes. The company generated free cash flow of $786.00M, which provides a robust buffer for capital expenditures, debt servicing, and potential strategic acquisitions, thereby ensuring significant financial flexibility. Profitability analysis shows a gross margin of 68.2%, indicating high pricing power or low cost of goods sold relative to revenue, while an operating margin of 19.7% and a profit margin of 19.6% demonstrate efficient conversion of sales into bottom-line earnings. On the liability side, the company holds $1.63B in cash against $2.55B in total debt, resulting in a debt-to-equity ratio of 93.76% which suggests a leveraged balance sheet typical for capital-intensive technology firms. Liquidity is well-managed with a current ratio of 2.08, indicating that current assets are more than double current liabilities and providing ample coverage for short-term obligations. Return metrics show a return on equity of 33.4% and a return on assets of 8.4%, signaling that management is effectively utilizing shareholder equity to generate returns, although the ROA reflects the capital intensity of the business model.
估值评估
The stock trades with a P/E ratio (TTM) of 22.69 and a forward P/E of 21.22, implying that the market expects earnings growth in the coming year as the forward multiple is lower than the trailing multiple. The price-to-book ratio stands at 6.95, suggesting that the market values the company at nearly seven times its book value, which often indicates a premium assigned to intangible assets like intellectual property and proprietary technology. Alternative valuation metrics include a price-to-sales ratio of 4.35 and an EV/EBITDA of 17.41, providing different lenses to assess value relative to revenue generation and operational cash flow potential. Regarding price action, the 52-week high is $155.53 and the 52-week low is $68.70; without a specific current price provided in the facts, the range defines the volatility envelope within which the stock has traded over the last year. The beta value is 1.49, indicating that the stock's price volatility is nearly 50% higher than the broader market, which implies higher risk and potential reward characteristics compared to large-cap peers.
Growth & Income
Revenue growth (YoY) is recorded at 5.0%, while earnings growth (YoY) stands at 86.4%, demonstrating that earnings are expanding significantly faster than revenue, likely driven by margin expansion or one-time non-recurring items impacting the net income calculation. As the dividend yield is N/A and the payout ratio is 0.0%, the company does not distribute dividends to shareholders, meaning the entire earnings stream is available for reinvestment into research and development or balance sheet strengthening. This reinvestment strategy aligns with the capital-intensive nature of the diagnostics industry, where continuous innovation in sequencing technology is required to maintain competitive positioning. Overall, the growth profile is characterized by strong earnings acceleration relative to top-line growth, while the income profile relies entirely on capital appreciation rather than dividend income for investors.